Oxindole

Oxindole

SCHEMBL4720301

O=C1Cc2ccccc2N1.[NaH]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 5/20 0.95
PDK2 Q15119 1/20 0.95
NPC1 O15118 2/20 0.63
MAPK13 O15264 1/20 0.63
MAPK12 P53778 1/20 0.63
MAPK11 Q15759 1/20 0.63
MAPK14 Q16539 1/20 0.63
MAPT P10636 2/20 0.59
TDP2 O95551 1/20 0.55
CASP3 P42574 1/20 0.55
CASP7 P55210 1/20 0.55
CASP9 P55211 1/20 0.55
CASP6 P55212 1/20 0.55
CASP8 Q14790 1/20 0.55
MAP3K14 Q99558 1/20 0.55
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
HSP90AA1 P07900 1/20 0.54
THRB P10828 1/20 0.54
HK1 P19367 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxindole SCHEMBL29358826 0.98 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL19504 0.98 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1144643 0.98 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1236964 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL15636313 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1462135 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL5502064 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL8866524 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL5668060 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL5624006 0.95 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101309904-A 1- (1H-indol-1-yl) -3- (methylamino) -1-phenylpropan-2-ol derivatives and related compounds as monoamine reuptake modulators for the treatment of vasomotor symptoms (VMS) WYETH CORP (US) 2008-11-19 CN disclosed
EP-1931631-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth a Corporation of the State of Delaware (US) 2008-06-18 EP disclosed
WO-2007041023-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2007-04-12 WO disclosed
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use COMT, PNMT, GLS AHR 628/4885PDK2 283/4885NPC1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.